Nuformix PLC Admission and First Dealings (6265T)
16 Outubro 2017 - 4:00AM
UK Regulatory
TIDMNFX
RNS Number : 6265T
Nuformix PLC
16 October 2017
16 October 2017
Notice of Admission to Trading on The Official List and to
Trading on the London Stock Exchange's Market for Regulated
Securities
Nuformix plc (ticker: NFX)
Following a Reverse Takeover on the London Stock Exchange's
market for regulated securities the undermentioned securities
Nuformix plc (formerly Levrett plc: named changed 13 October 2017)
will this morning be admitted to the standard segment of the
Official List and are expected to commence trading on the London
Stock Exchange's main market for listed securities this morning, 16
October 2017, at 8.00 a.m. ticker: NFX
Name: NUFORMIX PLC Security: ORDINARY SHARES
OF 0.1P EACH, FULLY
PAID
------- ------------- ---------- ---------------------
SEDOL: BYW79Y3 ISIN: GB00BYW79Y38
------- ------------- ---------- ---------------------
Nuformix Summary
Nuformix is a UK incorporated pharmaceutical development company
using cocrystal technology to unlock the therapeutic potential of
approved small molecule drugs. It has discovered, developed and
patented novel cocrystal forms of approved small molecules,
creating an IP portfolio containing 14 granted patents covering
cocrystal forms of five small molecule drugs. It has identified two
drug cocrystals that the Directors and Directors on Admission
believe represent stand-out commercial and therapeutic promise and
is seeking to progress these programmes to human pharmacokinetic
(PK) studies, funded by the Placing:
NXP001:
-- NXP001 is based on a currently marketed treatment in the
field of oncology supportive care, which addresses some of the
severe side effects faced by cancer patients in their
treatment.
-- It provides entry into the large and growing oncology
supportive care market, currently estimated at GBP17.5 billion per
annum, rising to GBP23.5 billion in 2021.
NXP002:
-- NKP0002 is based on a known drug for the treatment of
allergies. In this case, Nuformix seeks to reprofile the drug to
treat a range of fibrotic conditions, which can occur in organs
such as the lungs, liver or heart.
-- NXP002 provides a route into the large, emerging fibrosis
market, currently estimated at over $1 billion in the US for lung
fibrosis alone, with a safe and innovative treatment.
-- The Directors and Directors on Admission believe that there
is high unmet need in an exponentially growing and critically ill
patient population and strong potential for early out-licensing
given the potential to treat a breadth of fibrotic conditions.
Nuformix Strategy
The Directors and Directors on Admission believe that approved
drugs offer the potential to generate significant value in new
therapeutic uses, as proven safety reduces development risk/cost
and increases speed to clinic/market versus traditional biotech
models. Nuformix's strategy seeks to harnesses these strategic
advantages:
-- Identify known drug molecules with the potential to function
as innovative therapies for unmet medical needs
-- Use cocrystal technology to protect and enable such molecules
towards new commercially attractive product opportunities
-- Lower-risk human studies will provide validation to support
out-licensing and further development by pharmaceutical
partners
-- A balanced pipeline combines assets for early out-licensing
with those offering significant mid-term partnering potential
-- Early licensing revenues allow Nuformix to self-fund future
discovery and development and build greater value into our
pipeline
Development Pipeline
The Enlarged Group intends to use cocrystal technology as
applied to pharmaceutical development both for:
-- Innovative Generics: Deliver a material benefit to an
existing drug in its existing use, such that therapeutic and
commercial advantages are created (e.g. reduction of side
effects)
-- Drug Reprofiling: Creating novel uses for existing drug
molecules in areas of unmet need that would not be possible for the
pure drug form.
The Directors and Directors on Admission believe that this
approach will allow re-use of existing safety data, reducing the
time and cost of achieving clinical proof-of-concept and increasing
success rates versus traditional biotech models.
Nuformix has completed research partnerships with Vectura
Limited ("Vectura") (LSE:VEC) and Magnus Oxygen Limited ("Magnus").
Patents have been filed as a result of collaborative research in
each partnership.
Follow Nuformix on Vox Markets: follow at
www.voxmarkets.co.uk/company/NFX
and www.nuformix.com
Enquiries:
Nuformix plc
Dan Gooding, Chief Executive
Officer +44 (0)1223 423667
Whitman Howard Limited
Nick Lovering +44 (0)20 7659 1234
Gable Communications
Ltd
John Bick / Justine
James +44 (0)20 7193 7463
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISMABBTMBJBTTR
(END) Dow Jones Newswires
October 16, 2017 02:00 ET (06:00 GMT)
Levrett (LSE:LVRT)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Levrett (LSE:LVRT)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024